Results 1 to 10 of about 1,287,340 (324)

Crucial contribution of the universities to SARS-CoV-2 surveillance in Ecuador: Lessons for developing countries

One Health, 2021
COVID-19 pandemic has challenged public health systems worldwide, particularly affecting developing countries in Latin America like Ecuador. In this report, we exposed the fundamental role of the Ecuadorian universities to improve COVID-19 surveillance ...
Daniela Santander-Gordon, Gabriel A. Iturralde, Byron Freire-Paspuel, Marlon S. Zambrano-Mila, Diana Morales-Jadan, Paolo A. Vallejo-Janeta, Barbara Coronel, Heberson Galvis, Tatiana Jaramillo-Vivanco, Christian D. Bilvao, Maria Belen Paredes-Espinosa, Angel S. Rodriguez, Juan C. Laglaguano, Henry Herrera, Ana M. Tito-Alvarez, Esteban Ortiz-Prado, Ismar A. Rivera-Olivero, Aquiles R. Henriquez-Trujillo, Tannya Lozada, Miguel Angel Garcia-Bereguiain   +19 more
doaj   +1 more source

AmpliCoV: Rapid Whole-Genome Sequencing Using Multiplex PCR Amplification and Real-Time Oxford Nanopore MinION Sequencing Enables Rapid Variant Identification of SARS-CoV-2

Frontiers in Microbiology, 2021
Since the emergence of the Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) in December 2019, the scientific community has been sharing data on epidemiology, diagnostic methods, and whole-genomic sequences almost in real time. The latter have
Annika Brinkmann, Sophie-Luisa Ulm, Steven Uddin, Sophie Förster, Dominique Seifert, Rainer Oehme, Merle Corty, Lars Schaade, Janine Michel, Andreas Nitsche   +9 more
doaj   +1 more source

SARS-CoV-2 in silico binding affinity to human leukocyte antigen (HLA) Class II molecules predicts vaccine effectiveness across variants of concern (VOC)

Scientific Reports, 2022
There is widespread concern about the clinical effectiveness of current vaccines in preventing Covid-19 caused by SARS-CoV-2 Variants of Concern (Williams in Lancet Respir Med 29:333–335, 2021; Hayawi in Vaccines 9:1305, 2021), including those identified
Spyros A. Charonis, Lisa M. James, Apostolos P. Georgopoulos   +2 more
doaj   +1 more source

Evaluation of a commercial ELISA as alternative to plaque reduction neutralization test to detect neutralizing antibodies against SARS-CoV-2

Scientific Reports, 2022
High-throughput detection of neutralizing antibodies against SARS-CoV-2 presents a valuable tool for vaccine trials or investigations of population immunity.
Natalie Hofmann, Marica Grossegesse, Markus Neumann, Lars Schaade, Andreas Nitsche   +4 more
doaj   +1 more source

Longitudinal SARS-CoV-2 seroepidemiological investigation among healthcare workers at a tertiary care hospital in Germany

BMC Infectious Diseases, 2022
Background SARS-CoV-2 cases in Germany increased in early March 2020. By April 2020, cases among health care workers (HCW) were detected across departments at a tertiary care hospital in Berlin, prompting a longitudinal investigation to assess HCW SARS ...
Sara Tomczyk, Alexander Hönning, Julia Hermes, Marica Grossegesse, Natalie Hofmann, Janine Michel, Markus Neumann, Andreas Nitsche, Berthold Hoppe, Tim Eckmanns, Hajo Schmidt-Traub, Kristina Zappel   +11 more
doaj   +1 more source

Aerosol and Surface Stability of SARS-CoV-2 as Compared with SARS-CoV-1

New England Journal of Medicine, 2020
Aerosol and Surface Stability of SARS-CoV-2 In this research letter, investigators report on the stability of SARS-CoV-2 and SARS-CoV-1 under experimental conditions.
N. van Doremalen, T. Bushmaker, Dylan H. Morris, M. Holbrook, Amandine Gamble, Brandi N. Williamson, A. Tamin, J. Harcourt, N. Thornburg, S. Gerber, J. Lloyd-Smith, E. de Wit, V. Munster   +12 more
semanticscholar   +1 more source

Flexible upscaling of laboratory PCR testing capacity at the Robert Koch Institute during the SARS-CoV-2 pandemic

Virology Journal, 2023
Background Over the course of the COVID-19 pandemic, laboratories worldwide have been facing an unprecedented increase in demand for PCR testing because of the high importance of diagnostics for prevention and control of virus spread.
Eva Krause, Janine Michel, Andreas Puyskens, Natalie Hofmann, Thomas Rinner, Barbara Biere, Brigitte G. Dorner, Martin Skiba, Lars Schaade, Andreas Nitsche   +9 more
doaj   +1 more source

Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine

New England Journal of Medicine, 2020
Background Vaccines are needed to prevent coronavirus disease 2019 (Covid-19) and to protect persons who are at high risk for complications. The mRNA-1273 vaccine is a lipid nanoparticle–encapsulated mRNA-based vaccine that encodes the prefusion ...
L. Baden, Hana M. El Sahly, B. Essink, K. Kotloff, S. Frey, R. Novak, D. Diemert, S. Spector, N. Rouphael, C. Creech, J. Mcgettigan, Shishir Kehtan, N. Segall, Joel Solis, A. Brosz, C. Fierro, H. Schwartz, K. Neuzil, L. Corey, P. Gilbert, H. Janes, D. Follmann, M. Marovich, J. Mascola, L. Polakowski, J. Ledgerwood, B. Graham, H. Bennett, R. Pajon, C. Knightly, B. Leav, W. Deng, Honghong Zhou, Shu Han, M. Ivarsson, Jacqueline M. Miller, T. Zaks   +36 more
semanticscholar   +1 more source

Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2

Science, 2020
How SARS-CoV-2 binds to human cells Scientists are racing to learn the secrets of severe acute respiratory syndrome–coronavirus 2 (SARS-CoV-2), which is the cause of the pandemic disease COVID-19. The first step in viral entry is the binding of the viral
R. Yan, Yuanyuan Zhang, Yaning Li, L. Xia, Yingying Guo, Qiang Zhou   +5 more
semanticscholar   +1 more source

The proximal origin of SARS-CoV-2

Nature Medicine, 2020
SARS-CoV-2 is the seventh coronavirus known to infect humans; SARSCoV, MERS-CoV and SARS-CoV-2 can cause severe disease, whereas HKU1, NL63, OC43 and 229E are associated with mild symptoms6. Here we review what can be deduced about the origin of SARS-CoV-
Kristian G. Andersen, Kristian G. Andersen, A. Rambaut, W. Lipkin, E. Holmes, R. Garry   +5 more
semanticscholar   +1 more source